WUXI, China, Oct. 27, 2021 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, announced that it has completed a remote GMP ...

Guide covers five core components of 21 CFR Part 111 quality systems, common FDA cGMP violations, and tips for ...

The success of virtual GMP inspections performed during the pandemic may lead to more flexible opportunities in the future. A temporary system, under which good manufacturing practice (GMP) ...

SUZHOU, China, May 21, 2025 /PRNewswire/ -- BioDlink has achieved a significant milestone in regulatory compliance after successfully passing an on-site GMP inspection conducted by Brazil's National ...

It is very important for pharmaceutical companies to plan carefully for all Good Manufacturing Practice (GMP) inspections, as a successful outcome is required for continued operations. Careful ...

WUXI, China, Sept. 17, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced that three of its manufacturing ...

WUXI, China, April 6, 2021 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, today announced that it has successfully ...

HONG KONG – Aiming to address a perceived disparity in the quality of manufacturing of drugs for the China market, the CFDA is ramping up its focus on offshore drug manufacturers. The regulator last ...